Skin atrophy adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 5,651 adverse event reports that record the MedDRA preferred term Skin atrophy. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 352 reports in the 12 months to June 2026 and 348 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,166 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 352 (under 0.1%) record this term. Reports for female patients were 60% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 150 drug pages with 10 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Skin atrophy name as a suspect product, in order of name
Drug	Class	Reports with this term
Actemra	Interleukin-6 receptor antagonist	62
Advair Diskus	Corticosteroid	10
Advair Diskus 100/50		26
Advair Hfa	Corticosteroid	22
Afinitor	Kinase inhibitor	10
Albuterol sulfate	beta2-Adrenergic agonist	27
Alli	Intestinal lipase inhibitor	17
Amlodipine	Calcium channel blocker	12
Anastrozole	Aromatase inhibitor	37
Aspirin	Nonsteroidal anti-inflammatory drug	20
Atenolol	beta-Adrenergic blocker	10
Atorvastatin		23
Atorvastatin calcium	HMG-CoA reductase inhibitor	19
Avonex	Interferon beta	41
Ayvakit	Kinase inhibitor	14
Betamethasone		16
Betamethasone dipropionate	Corticosteroid	15
Betamethasone valerate	Corticosteroid	16
Betnovate		12
Breo Ellipta	Corticosteroid	27
Brilinta	P2Y12 platelet inhibitor	14
Cabometyx	Kinase inhibitor	55
Celebrex	Nonsteroidal anti-inflammatory drug	10
Ciclosporin		28
Ciprofloxacin	Fluoroquinolone antibacterial	17
Clobetasol		37
Clobetasol propionate	Corticosteroid	68
Clonazepam	Benzodiazepine	11
Copaxone		11
Corticotropin		33
Cosentyx	Interleukin-17A antagonist	121
Coumadin		12
Cyclophosphamide	Alkylating drug	14
Cyclosporine	Calcineurin inhibitor immunosuppressant	33
Dapagliflozin	Sodium-Glucose cotransporter 2 inhibitor	11
Dexamethasone	Corticosteroid	30
Docetaxel	Microtubule inhibitor	11
Dupilumab	Interleukin-4 receptor alpha antagonist	19
Dupixent	Interleukin-4 receptor alpha antagonist	283
Elidel		14
Eliquis	Factor Xa inhibitor	55
Elocon		18
Enbrel	Tumor necrosis factor blocker	252
Ergocalciferol	Provitamin D2 compound	27
Eucrisa	Phosphodiesterase 4 inhibitor	13
Eumovate		38
Finasteride	5-alpha reductase inhibitor	54
Fluorouracil	Nucleoside metabolic inhibitor	13
Fluticasone Propionate Salmeterol Xinafoate		12
Forteo	Parathyroid hormone analog	51
Fosamax	Bisphosphonate	11
Fulvestrant	Estrogen receptor antagonist	18
Furosemide	Loop diuretic	33
Gabapentin	Anti-epileptic agent	22
Gleevec	Kinase inhibitor	23
Human immunoglobulin g	Human immunoglobulin G	10
Humira		256
Hydrocortisone	Corticosteroid	84
Hydroxychloroquine	Antimalarial	16
Ibrance	Kinase inhibitor	32
Ibuprofen	Nonsteroidal anti-inflammatory drug	36
Imbruvica	Kinase inhibitor	110
Iodine		25
Jakafi	Janus kinase inhibitor	23
Kenalog		25
Kenalog-40	Corticosteroid	18
Kisqali	Kinase inhibitor	50
Klonopin	Benzodiazepine	12
Lamisil		26
Lasix	Loop diuretic	11
Letrozole	Aromatase inhibitor	21
Levofloxacin	Fluoroquinolone antibacterial	26
Lioresal (baclofen)	gamma-Aminobutyric acid-ergic agonist	14
Losartan	Angiotensin 2 receptor blocker	10
Lyrica		25
Magnevist		21
Medrol	Corticosteroid	11
Mepolizumab	Interleukin-5 antagonist	17
Metformin	Biguanide	18
Methotrexate	Folate analog metabolic inhibitor	156
Methotrexate sodium	Folate analog metabolic inhibitor	34
Methylprednisolone	Corticosteroid	18
Mometasone	Corticosteroid	26
Mometasone furoate	Corticosteroid	39
MultiHance	Gadolinium-based contrast agent	10
Nucala	Interleukin-5 antagonist	31
Ocrevus	CD20-directed cytolytic antibody	11
Ofev	Kinase inhibitor	14
Omeprazole	Proton pump inhibitor	26
Omniscan	Paramagnetic contrast agent	18
Opdivo	Programmed death Receptor-1 blocking antibody	10
Optimark		13
Orgovyx	Gonadotropin releasing hormone receptor antagonist	10
Otezla	Phosphodiesterase 4 inhibitor	33
Ozempic	GLP-1 receptor agonist	12
Pantoprazole	Proton pump inhibitor	13
Pegasys	Interferon alpha	11
Pembrolizumab	Programmed death Receptor-1 blocking antibody	11
Plavix	P2Y12 platelet inhibitor	18
Pradaxa	Direct thrombin inhibitor	11
Praluent	PCSK9 inhibitor	11
Prednisolone	Corticosteroid	102
Prednisone	Corticosteroid	282
Premarin	Estrogen	19
Prolia	RANK ligand inhibitor	25
Propecia	5-alpha reductase inhibitor	14
Protopic		42
Quetiapine	Atypical antipsychotic	17
Quetiapine fumarate	Atypical antipsychotic	10
Ramipril	Angiotensin converting enzyme inhibitor	11
Remicade	Tumor necrosis factor blocker	14
Repatha	PCSK9 inhibitor	13
Repository corticotropin	Adrenocorticotropic hormone	14
Revlimid	Thalidomide analog	103
Ribavirin	Nucleoside analog antiviral	12
Rinvoq	Janus kinase inhibitor	35
Rituxan	CD20-directed cytolytic antibody	20
Rituximab	CD20-directed cytolytic antibody	20
Rosuvastatin	HMG-CoA reductase inhibitor	12
Salbutamol		20
Salbutamol sulfate		15
Sandostatin	Somatostatin analog	11
Sandostatin LAR Depot		16
Seretide		12
Seroquel	Atypical antipsychotic	11
Simvastatin	HMG-CoA reductase inhibitor	19
Singulair	Leukotriene receptor antagonist	20
Skyrizi	Interleukin-23 antagonist	46
Strensiq		17
Sulfasalazine	Aminosalicylate	23
Sutent	Kinase inhibitor	50
Symbicort	Corticosteroid	29
Tacrolimus	Calcineurin inhibitor immunosuppressant	26
Tagrisso	Kinase inhibitor	16
Tamoxifen		12
Tarceva		10
Tarpeyo	Corticosteroid	32
Tecfidera		13
Tiotropium bromide	Anticholinergic	17
Triamcinolone		43
Triamcinolone acetonide	Corticosteroid	72
Tylenol	Expectorant	11
Tysabri	Integrin receptor antagonist	17
Votrient	Kinase inhibitor	17
Xarelto	Factor Xa inhibitor	54
Xeljanz	Janus kinase inhibitor	67
Xeloda	Nucleoside metabolic inhibitor	13
Xolair	Anti-IgE	38
Zometa		37
Zytiga	Cytochrome P450 17A1 inhibitor	16

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 43 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Skin atrophy name, in order of name
Class	Reports with this term
5-alpha reductase inhibitor	72
Anti-epileptic agent	51
Anti-IgE	47
Anticholinergic	31
Antimalarial	30
Aromatase inhibitor	65
Atypical antipsychotic	43
Benzodiazepine	33
beta2-Adrenergic agonist	29
Calcineurin inhibitor immunosuppressant	63
CD20-directed cytolytic antibody	55
Corticosteroid	952
Estrogen	25
Estrogen receptor antagonist	25
Factor Xa inhibitor	117
Fluoroquinolone antibacterial	48
Folate analog metabolic inhibitor	192
gamma-Aminobutyric acid-ergic agonist	26
GLP-1 receptor agonist	46
HMG-CoA reductase inhibitor	62
Integrin receptor antagonist	26
Interferon beta	49
Interleukin-17A antagonist	126
Interleukin-23 antagonist	55
Interleukin-4 receptor alpha antagonist	302
Interleukin-5 antagonist	48
Interleukin-6 receptor antagonist	71
Janus kinase inhibitor	135
Kinase inhibitor	478
Leukotriene receptor antagonist	29
Loop diuretic	46
Nonsteroidal anti-inflammatory drug	84
Nucleoside metabolic inhibitor	28
P2Y12 platelet inhibitor	38
Paramagnetic contrast agent	27
Parathyroid hormone analog	51
Phosphodiesterase 4 inhibitor	46
Programmed death Receptor-1 blocking antibody	33
Proton pump inhibitor	51
Provitamin D2 compound	30
RANK ligand inhibitor	29
Thalidomide analog	117
Tumor necrosis factor blocker	299

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Skin atrophy, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Skin atrophy
Age	Reports	Share
Under 2	22	0.4%
2 to 11	52	0.9%
12 to 17	49	0.9%
18 to 44	636	11.3%
45 to 64	1,255	22.2%
65 to 74	819	14.5%
75 and over	699	12.4%
Age not given	2,119	37.5%

Sex of the patient in the reports that record Skin atrophy
Sex	Reports	Share
Female	3,390	60%
Male	1,850	32.7%
Unknown or not given	411	7.3%

Age and sex are as the report gives them. 64.3% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Skin atrophy: adverse event reports that record this term. https://reportedreactions.com/reaction/skin-atrophy/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Skin atrophy mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page